Literature DB >> 17608623

Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity.

Jun Li1, Christine Tumanut, Julie-Ann Gavigan, Waan-Jeng Huang, Eric N Hampton, Rachelle Tumanut, Ka Fai Suen, John W Trauger, Glen Spraggon, Scott A Lesley, Gene Liau, David Yowe, Jennifer L Harris.   

Abstract

PCSK9 (proprotein convertase subtilisin/kexin 9) is a secreted serine protease that regulates cholesterol homoeostasis by inducing post-translational degradation of hepatic LDL-R [LDL (low-density lipoprotein) receptor]. Intramolecular autocatalytic processing of the PCSK9 zymogen in the endoplasmic reticulum results in a tightly associated complex between the prodomain and the catalytic domain. Although the autocatalytic processing event is required for proper secretion of PCSK9, the requirement of proteolytic activity in the regulation of LDL-R is currently unknown. Co-expression of the prodomain and the catalytic domain in trans allowed for production of a catalytically inactive secreted form of PCSK9. This catalytically inactive PCSK9 was characterized and shown to be functionally equivalent to the wild-type protein in lowering cellular LDL uptake and LDL-R levels. These findings suggest that, apart from autocatalytic processing, the protease activity of PCSK9 is not necessary for LDL-R regulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608623      PMCID: PMC1948958          DOI: 10.1042/BJ20070664

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

2.  LDL-receptor structure. Calcium cages, acid baths and recycling receptors.

Authors:  M S Brown; J Herz; J L Goldstein
Journal:  Nature       Date:  1997-08-14       Impact factor: 49.962

3.  The alpha-lytic protease pro-region does not require a physical linkage to activate the protease domain in vivo.

Authors:  J L Silen; D A Agard
Journal:  Nature       Date:  1989-10-05       Impact factor: 49.962

Review 4.  The role of pro regions in protein folding.

Authors:  D Baker; A K Shiau; D A Agard
Journal:  Curr Opin Cell Biol       Date:  1993-12       Impact factor: 8.382

5.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

Authors:  Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

6.  Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

Authors:  Zhenze Zhao; Yetsa Tuakli-Wosornu; Thomas A Lagace; Lisa Kinch; Nicholas V Grishin; Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Am J Hum Genet       Date:  2006-07-18       Impact factor: 11.025

7.  Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

Authors:  Kara N Maxwell; Edward A Fisher; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-27       Impact factor: 11.205

8.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

9.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

10.  NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.

Authors:  Suzanne Benjannet; David Rhainds; Rachid Essalmani; Janice Mayne; Louise Wickham; Weijun Jin; Marie-Claude Asselin; Josée Hamelin; Mathilde Varret; Delphine Allard; Mélanie Trillard; Marianne Abifadel; Angie Tebon; Alan D Attie; Daniel J Rader; Catherine Boileau; Louise Brissette; Michel Chrétien; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2004-09-09       Impact factor: 5.157

View more
  52 in total

1.  Blackcurrant anthocyanins stimulated cholesterol transport via post-transcriptional induction of LDL receptor in Caco-2 cells.

Authors:  Bohkyung Kim; Minkyung Bae; Young-Ki Park; Hang Ma; Tao Yuan; Navindra P Seeram; Ji-Young Lee
Journal:  Eur J Nutr       Date:  2017-07-17       Impact factor: 5.614

2.  PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day.

Authors:  Yan Q Chen; Jason S Troutt; Robert J Konrad
Journal:  Lipids       Date:  2014-05       Impact factor: 1.880

Review 3.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

Review 4.  Cholesterol, the central lipid of mammalian cells.

Authors:  Frederick R Maxfield; Gerrit van Meer
Journal:  Curr Opin Cell Biol       Date:  2010-06-02       Impact factor: 8.382

5.  High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.

Authors:  Greg Welder; Issam Zineh; Michael A Pacanowski; Jason S Troutt; Guoqing Cao; Robert J Konrad
Journal:  J Lipid Res       Date:  2010-06-05       Impact factor: 5.922

Review 6.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

7.  Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.

Authors:  Kévin Ly; Yascara Grisel Luna Saavedra; Maryssa Canuel; Sophie Routhier; Roxane Desjardins; Josée Hamelin; Janice Mayne; Claude Lazure; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

8.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

Authors:  Joyce C Y Chan; Derek E Piper; Qiong Cao; Dongming Liu; Chadwick King; Wei Wang; Jie Tang; Qiang Liu; Jared Higbee; Zhen Xia; Yongmei Di; Susan Shetterly; Ziva Arimura; Heather Salomonis; William G Romanow; Stephen T Thibault; Richard Zhang; Ping Cao; Xiao-Ping Yang; Timothy Yu; Mei Lu; Marc W Retter; Gayle Kwon; Kirk Henne; Oscar Pan; Mei-Mei Tsai; Bryna Fuchslocher; Evelyn Yang; Lei Zhou; Ki Jeong Lee; Mark Daris; Jackie Sheng; Yan Wang; Wenyan D Shen; Wen-Chen Yeh; Maurice Emery; Nigel P C Walker; Bei Shan; Margrit Schwarz; Simon M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

9.  Small Molecule Inhibitors of the PCSK9·LDLR Interaction.

Authors:  Jaru Taechalertpaisarn; Bosheng Zhao; Xiaowen Liang; Kevin Burgess
Journal:  J Am Chem Soc       Date:  2018-02-26       Impact factor: 15.419

10.  Plasma PCSK9 preferentially reduces liver LDL receptors in mice.

Authors:  Aldo Grefhorst; Markey C McNutt; Thomas A Lagace; Jay D Horton
Journal:  J Lipid Res       Date:  2008-03-19       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.